Article Figures & Data
Figures
- Figure 1.
The number of circulating tumor cells (CTCs) in gynecological cancer patients. (A) CTCs isolated from whole blood from the 20 gynecological cancer patients using a size-selective CTC isolation platform. The number of CTCs were quantified by counting anti-EpCAM and anti-cytokeratin among all mononuclear cells. (B) CTC numbers are determined in gynecological cancer patients of different clinical stages (means±SD, **p<0.005, Student's t-test).
- Figure 2.
The performance of the customized NGS panel was measured using cfDNA reference standard or the blood spiking PC9 cells, respectively. (A) The average allele frequency of eight variants (triplicate, y-axis) as a function of the expected allele frequency (x-axis) for the Horizon cfDNA reference standards. (B) The 10- and 100-PC9 cell pools were generated by serial dilutions. Cultured KOREF cells and PC9 cells used as EGFR exon 19 deleted negative cells and positive cells, respectively.
- Figure 3.
The combinatory analysis of genetic alterations using cfDNA and ctcDNA. (A) Venn diagram of matched cfDNA variants (blue) and ctcDNA (grey). The genetic alterations in cfDNA and ctcDNA in gynecological cancer patients. Nine genetic variants (red) were shared between cfDNA and ctcDNA. Four variants matched in cfDNA and ctcDNA of same patients. (B) The percentage of patients with mutations detected using combination, cfDNA or ctcDNA alone. Multiple genetic variants within the same gene in each patient were counted as one.
